Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.16
  • Today's Change0.14 / 0.50%
  • Shares traded790.74k
  • 1 Year change-16.96%
  • Beta0.4873
Data delayed at least 15 minutes, as of Sep 18 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.

  • Revenue in USD (TTM)4.43bn
  • Net income in USD-113.90m
  • Incorporated2013
  • Employees9.14k
  • Location
    Perrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
  • Phone+353 17094000
  • Websitehttps://www.perrigo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amphastar Pharmaceuticals Inc712.89m166.52m2.37bn1.76k15.503.3410.783.323.143.1413.4514.570.49682.856.04404,821.7011.719.4213.5411.5654.6847.8323.5615.232.637.420.45150.0029.1416.9450.51---4.00--
Catalyst Pharmaceuticals Inc434.48m68.15m2.43bn167.0038.313.9823.175.580.53350.53353.715.140.75544.038.692,601,647.0011.8525.4213.5629.8186.6785.6315.6930.874.94--0.000.0085.90280.39-14.05--20.21--
Amneal Pharmaceuticals Inc2.60bn-174.62m2.73bn7.70k----29.701.05-0.6224-0.622410.09-0.18570.72063.003.60337,401.60-3.69-4.80-4.93-5.9335.0434.76-5.13-9.000.81651.241.00--8.207.5635.38---6.55--
Twist Bioscience Corp295.21m-220.31m2.79bn919.00--5.68--9.46-3.81-3.815.128.390.40765.428.56321,229.60-30.42-30.50-33.85-33.8440.5336.02-74.63-113.334.52--0.00--20.4157.336.08--49.76--
Prestige Consumer Healthcare Inc1.11bn205.13m3.64bn570.0018.002.1715.423.274.094.0922.1833.920.33463.096.751,952,965.006.173.696.423.8455.3256.7918.4312.191.905.260.39390.00-0.212.89354.34---1.84--
Perrigo Company PLC4.43bn-113.90m3.82bn9.14k--0.840916.890.8632-0.833-0.910632.3733.320.41462.485.78484,496.70-1.07-0.1148-1.21-0.131535.9335.28-2.57-0.29851.241.150.4717--4.58-0.323896.64---5.957.52
Corcept Therapeutics Incorporated569.61m125.98m4.15bn352.0034.936.9532.697.281.141.145.145.710.91931.1213.191,618,210.0020.3321.1724.1023.8598.4998.5222.1227.235.48--0.000.0020.0413.934.667.08-14.15--
Apellis Pharmaceuticals Inc628.79m-332.89m4.33bn702.00--16.36--6.88-2.74-2.745.152.170.69100.6693.03895,706.60-36.58-73.88-45.11-90.0386.38---52.94-326.494.18-17.870.6337--425.83--18.94------
ADMA Biologics Inc330.24m34.79m4.36bn624.00133.0623.16101.0613.210.14060.14061.410.80790.91811.049.88529,237.609.67-24.8010.99-28.0046.1217.4010.53-51.312.804.590.4105--67.5972.3457.15--18.91--
Axsome Therapeutics Inc291.49m-308.55m4.37bn545.00--42.27--14.98-6.51-6.516.152.150.50262.313.11534,842.20-53.20-64.55-71.90-82.2390.30---105.85-227.052.40-79.610.6409--440.80---27.84--77.86--
Avidity Biosciences Inc10.60m-252.45m4.92bn253.00--3.78--464.08-2.95-2.950.123111.170.0108--17.9241,893.28-25.78-31.61-27.61-34.45-----2,381.82-1,540.50----0.00--3.6490.71-21.97--143.89--
BridgeBio Pharma Inc219.12m-453.82m5.03bn550.00------22.94-2.64-2.641.24-5.810.3376----398,407.30-71.11-72.44-89.59-89.7298.9194.41-210.62-1,225.66---9.632.70---88.02---33.67---40.94--
Organon & Co6.35bn1.00bn5.29bn10.00k5.2936.744.230.83383.893.8924.650.55930.54872.113.86634,600.008.6516.5311.1220.9758.5965.1215.7626.791.172.370.98368.251.44-8.5211.56-13.8320.72--
Data as of Sep 18 2024. Currency figures normalised to Perrigo Company PLC's reporting currency: US Dollar USD

Institutional shareholders

43.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202414.59m10.70%
BlackRock Fund Advisorsas of 30 Jun 202411.66m8.55%
Dimensional Fund Advisors LPas of 30 Jun 20246.85m5.03%
SSgA Funds Management, Inc.as of 30 Jun 20246.83m5.01%
DePrince, Race & Zollo, Inc.as of 30 Jun 20243.88m2.85%
Davenport & Co. LLCas of 30 Jun 20243.56m2.61%
Cooke & Bieler LPas of 30 Jun 20243.50m2.57%
Thompson, Siegel & Walmsley LLCas of 30 Jun 20243.15m2.31%
JOHCM (USA), Inc.as of 30 Jun 20242.66m1.95%
Philosophy Capital Management LLCas of 30 Jun 20242.40m1.76%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.